Arcturus Therapeutics price target lowered to $72 from $140 at Piper Sandler

Piper Sandler lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $72 from $140 and keeps an Overweight rating on the shares after the company reported Q3 earnings and provided a comprehensive update across their ARCT-032 CF and ARCT-810 OTC deficiency programs. The company discussed that they are on track to reach regulatory alignment on a pivotal ARCT-810 OTC deficiency program in the first half of 2026 where there will likely be two separate conversations for adult and pediatric populations. In regard to KOSTAIVE, management noted the U.S. BLA filing has been delayed indefinitely due to regulatory changes and uncertain U.S. commercial viability with reduction of additional expenses. Thus, Piper views the first half of 2026 as an important inflection point for the name with updates expected across both CF and OTC programs.